• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by P3 Health Partners Inc.

    11/14/24 4:33:46 PM ET
    $PIII
    Medical/Nursing Services
    Health Care
    Get the next $PIII alert in real time by email
    SC 13G 1 alyeska-piii093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    P3 Health Partners Inc.

    (Name of Issuer)

     

    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    744413105

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  744413105
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Investment Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    16,014,443
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    16,014,443
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    16,014,443
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99% *
    12
    TYPE OF REPORTING PERSON
     
    IA

    The reporting persons are the beneficial owners of 15,697,751 shares of Class A common stock, par value $0.0001 per share of the Issuer and hold warrants to purchase 19,403,166 shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Warrants”) The percentage calculation assumes that there are currently 161,762,058 outstanding shares of Class A common stock, par value $0.0001 per share of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

     


     

    CUSIP No.  744413105
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Fund GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    16,014,443
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    16,014,443
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    16,014,443
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%*
    12
    TYPE OF REPORTING PERSON
     
    OO

    The reporting persons are the beneficial owners of 15,697,751 shares of Class A common stock, par value $0.0001 per share of the Issuer and hold warrants to purchase 19,403,166 shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Warrants”) The percentage calculation assumes that there are currently 161,762,058 outstanding shares of Class A common stock, par value $0.0001 per share of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

     


     

    CUSIP No.  744413105
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Anand Parekh
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    16,014,443
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    16,014,443
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    16,014,443
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    9.99%
    12
    TYPE OF REPORTING PERSON
     
    IN
    The reporting persons are the beneficial owners of 15,697,751 shares of Class A common stock, par value $0.0001 per share of the Issuer and hold warrants to purchase 19,403,166 shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Warrants”). The percentage calculation assumes that there are currently 161,762,058 outstanding shares of Class A common stock, par value $0.0001 per share of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024.
     


     

     

    CUSIP No. 744413105
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    P3 Health Partners Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    2370 Corporate Circle Suite 300

    Henderson, Nevada 89074

    Item 2.(a) Names of Person Filing:

    (i) Alyeska Investment Group, L.P.

     

    (ii) Alyeska Fund GP, LLC

     

    (iii) Anand Parekh

      

    Item 2.(b) Address of Principal Business Office:

    (i) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (ii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (iii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

      

    Item 2.(c) Citizenship:

    (i) Alyeska Investment Group, L.P. - Delaware

     

    (ii) Alyeska Fund GP, LLC - Delaware

     

    (iii) Anand Parekh - United States of America

      

    Item 2.(d) Title of Class of Securities

    Class A common stock, par value $0.0001 per share

     

    Item 2.(e) CUSIP No.:

    744413105

     

    CUSIP No.  744413105
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 744413105
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached hereto

    (c) Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto

    The reporting persons are the beneficial owners of 15,697,751 shares of Class A common stock, par value $0.0001 per share of the Issuer and hold warrants to purchase 19,403,166 shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Warrants”).  However, per their terms, the Warrants can only be exercised into such number of shares that would constitute 9.9% of the total number of Class A common stock, par value $0.0001 per share of the Issuer outstanding immediately after giving effect to the issuance of shares of Class A common stock, par value $0.0001 per share upon exercise of this Warrant by the Holder.  Accordingly, as of September 30, 2024 the reporting persons may only exercise up to 316,692  shares of Class A common stock, par value $0.0001 per share under the Warrant Agreement, and as such, is reporting beneficial ownership of only such number of shares.  The percentage calculation assumes that there are currently 161,762,058 outstanding shares of Class A common stock, par value $0.0001 per share of the Issuer, based on the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 744413105
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

    By:  Entity and Description

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           

     

     
    CUSIP No. 744413105
     SCHEDULE 13G
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           
    Get the next $PIII alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PIII

    DatePrice TargetRatingAnalyst
    4/1/2024Buy → Neutral
    BTIG Research
    9/1/2023$5.00Buy
    BTIG Research
    6/30/2023Market Perform
    TD Cowen
    1/4/2022Outperform
    William Blair
    More analyst ratings

    $PIII
    Leadership Updates

    Live Leadership Updates

    See more
    • P3 Health Partners Names Leif Pedersen New Chief Financial Officer

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, announced today that Leif Pedersen, an experienced finance, operational and value-based care executive, will join the company as chief financial officer (CFO) effective October 1, 2024. Pedersen succeeds Atul Kavthekar, who will continue as CFO until September 30, 2024, after which he will serve as a Strategic Advisor to the company. Pedersen was most recently Vice President of Finance & CFO Shared Services for Optum Health, a division of UnitedHealth Group. Prior to Optum Health, Pedersen served as Vice President of Finance & CFO IT at DaVita Medical Group. He brings m

      8/29/24 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Names Dr. Aric Coffman as CEO

      P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), today named Dr. Aric Coffman as P3's Chief Executive Officer, effective as of May 8, 2024, succeeding Dr. Sherif Abdou, P3's Co-Founder. Dr. Abdou will continue to serve as a Strategic Advisor to P3, and a member of the Company's Board of Directors working closely with Dr. Coffman to ensure a smooth transition. Dr. Coffman is an exceptional physician leader with a proven track record of success in the value-based care sector, most recently as the CEO of Honest Medical Group, a Rubicon Founders portfolio company. He brings over two decades of experience in leading provider organizations in delivering high quality, highly effici

      5/8/24 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • P3 Health Partners Schedules First Quarter 2025 Earnings Release and Conference Call

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2025 and file its Quarterly Report on Form 10-Q on Thursday, May 15, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health First Quarter Earnings Conference Call Date & Time May 15, 2025, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partners call

      5/8/25 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners to Participate in the 24th Annual Needham Virtual Healthcare Conference

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that it will participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. Management will give a presentation on Thursday, April 10, 2025, at 9:45 AM Pacific Time. A webcast of the presentation will be available on P3's Investor Relations Website at https://ir.p3hp.org/. A replay will be available on P3's investor relations webpage for 30 days following the presentation. About P3 Health Partners (NASDAQ:PIII): P3 Health Partners Inc. is a leading population health management company committed to transforming healthcare by improving the

      4/2/25 8:05:00 AM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results

      Revenue increased 18% year-over-year to $1.50 billion Affirming 2025 guidance Management to Host Conference Call and Webcast [March 27, 2025] at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient- centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance. "Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention," said Aric Coffman, CEO of P3. "With the $130M+ in identified programmatic opportunities advancing our path to financial su

      3/27/25 4:22:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Financials

    Live finance-specific insights

    See more
    • P3 Health Partners Schedules First Quarter 2025 Earnings Release and Conference Call

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for first quarter 2025 and file its Quarterly Report on Form 10-Q on Thursday, May 15, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health First Quarter Earnings Conference Call Date & Time May 15, 2025, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partners call

      5/8/25 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Announces Fourth Quarter and Full Year 2024 Results

      Revenue increased 18% year-over-year to $1.50 billion Affirming 2025 guidance Management to Host Conference Call and Webcast [March 27, 2025] at 4:30 PM ET P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ:PIII), a patient- centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and affirmed its 2025 guidance. "Our business model remains fundamentally strong as we continue to deliver member and top-line growth, quality outcomes, and provider retention," said Aric Coffman, CEO of P3. "With the $130M+ in identified programmatic opportunities advancing our path to financial su

      3/27/25 4:22:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners to Report Fourth Quarter and Full Year 2024 Financial Results on March 27

      P3 Health Partners Inc. ("P3") (NASDAQ:PIII), a patient-centered and physician-led population health management company, today announced that the Company plans to release its financial results for the fourth quarter and full year 2024 on March 27, 2025. In connection with the release, management will host a conference call to discuss the financial results at 1:30pm PT/ 4:30pm ET the same day. Title & Webcast P3 Health Fourth Quarter Earnings Conference Call Date & Time March 27, 2025, 4:30pm Eastern Time Conference Call Details Toll-Free 1-833-316-0546 (US) International 1-412-317-0692 Ask to be joined into the P3 Health Partners call   The conference call will

      3/13/25 4:05:00 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    SEC Filings

    See more
    • SEC Form DEF 14A filed by P3 Health Partners Inc.

      DEF 14A - P3 Health Partners Inc. (0001832511) (Filer)

      4/29/25 4:27:49 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • SEC Form PRE 14A filed by P3 Health Partners Inc.

      PRE 14A - P3 Health Partners Inc. (0001832511) (Filer)

      4/18/25 5:28:07 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • P3 Health Partners Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - P3 Health Partners Inc. (0001832511) (Filer)

      4/16/25 8:09:19 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $81,552 worth of shares (160,000 units at $0.51) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/13/24 9:56:09 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $128,624 worth of shares (240,000 units at $0.54) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/12/24 8:12:24 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $117,544 worth of shares (240,000 units at $0.49) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/11/24 6:17:20 AM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Chicago Pacific Founders Ugp Iii, Llc

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      1/31/25 7:05:33 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • SEC Form 3 filed by new insider Pedersen Leif Elliott

      3 - P3 Health Partners Inc. (0001832511) (Issuer)

      10/1/24 5:35:14 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Large owner Chicago Pacific Founders Ugp Iii, Llc bought $81,552 worth of shares (160,000 units at $0.51) (SEC Form 4)

      4 - P3 Health Partners Inc. (0001832511) (Issuer)

      9/13/24 9:56:09 PM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • P3 Health Partners downgraded by BTIG Research

      BTIG Research downgraded P3 Health Partners from Buy to Neutral

      4/1/24 7:39:12 AM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • BTIG Research initiated coverage on P3 Health Partners with a new price target

      BTIG Research initiated coverage of P3 Health Partners with a rating of Buy and set a new price target of $5.00

      9/1/23 7:31:24 AM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • TD Cowen initiated coverage on P3 Health Partners

      TD Cowen initiated coverage of P3 Health Partners with a rating of Market Perform

      6/30/23 7:34:42 AM ET
      $PIII
      Medical/Nursing Services
      Health Care

    $PIII
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by P3 Health Partners Inc.

      SC 13G - P3 Health Partners Inc. (0001832511) (Subject)

      11/14/24 4:33:46 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by P3 Health Partners Inc.

      SC 13D/A - P3 Health Partners Inc. (0001832511) (Subject)

      11/8/24 5:15:05 PM ET
      $PIII
      Medical/Nursing Services
      Health Care
    • Amendment: SEC Form SC 13D/A filed by P3 Health Partners Inc.

      SC 13D/A - P3 Health Partners Inc. (0001832511) (Subject)

      6/26/24 4:30:49 PM ET
      $PIII
      Medical/Nursing Services
      Health Care